University Lecturer (Clinical), Department of Paediatrics
I have a specialist clinical and research interest in paediatric diabetes mellitus and paediatric endocrinology
My main area of diabetes related research include studies into the pathophysiology of insulin resistance in children and adolescents with Type 1 and the development of novel therapeutic approaches to improve glycaemic control in patients with diabetes.
My paediatric endocrine research includes studies related to the epidemiology and natural history of traumatic brain injury induced hypothalamic-pituitary dysfunction. I also have a major interest in the rapidly developing area of endocrine disrupting chemicals (EDC’s) and their potential effects on human physiology and development. I am one of the principle investigators co-ordinating the Cambridge Baby Growth Study (est. 2001), which is a prospective, longitudinal study designed to assess the impact of genetic factors and the role of the maternal in-utero environment (including exposure to EDC’s) on influencing pre / postnatal growth and reproductive health.
Other research areas include: coeliac disease in Type 1 diabetes; pathophysiology of congenital adrenal hyperplasia.
McDonald A, Lindell M, Dunger DB, Acerini CL. Traumatic brain injury is a rarely reported cause of growth hormone deficiency. J Pediatr. 2008 Apr;152(4):590-3.Abstract
Almerie QM, Williams RM, Acerini CL. Should Angiotensin converting enzyme inhibitors be used in children with Type 1 diabetes and Microalbuminuria? Arch Dis Child. 2008 Feb 19; Abstract
Fröhlich-Reiterer EE, Ong KK, Regan F, Salzano G, Acerini CL, Dunger DB. A randomized cross-over trial to identify the optimal use of insulin glargine in prepubertal children using a three-times daily insulin regimen. Diabet Med. 2007 Dec;24(12):1406-11. Abstract
Kapoor RR, Burke SA, Sparrow SE, Hughes IA, Dunger DB, Ong KK, Acerini CL. Monitoring of concordance in growth hormone therapy. Arch Dis Child. 2008 Feb;93(2):147-8. Epub 2007 Sep 3. Abstract
Acerini CL, Tasker RC, Bellone S, Bona G, Thompson CJ, Savage MO. Hypopituitarism in childhood and adolescence following traumatic brain injury: the case for prospective endocrine investigation Eur J Endocrinol. 2006 Nov;155(5):663-9. Abstract
Acerini CL, Hughes IA. Endocrine disrupting chemicals: a new and emerging public health problem? Arch Dis Child. 2006 Aug;91(8):633-41. Abstract
Williams RM, Yuen K, White D, Mallard B, Dalton RN, Acerini CL, Dunger DB.
Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates. Clin Endocrinol (Oxf). 2006 Oct;65(4):439-45. Abstract
Buck JJ, Williams RM, Hughes IA, Acerini CL. In utero androgen exposure and 2nd to 4th digit length ratio – comparisons between healthy controls and females with classical congenital adrenal hyperplasia. Human Reproduction 2003 May;18(5):976-9. Abstract
David B. Savage, Garry D. Tan, Carlo L. Acerini, et al. The human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor PPARg. Diabetes 2003 Apr;52(4):910-7. Abstract
Acerini, C.L., Cheetham, T.D., Edge, J.A., Dunger, D.B. Both insulin sensitivity and insulin clearance in children with type 1 (insulin-dependent ) diabetes vary with growth hormone levels and with age Diabetologia 2000; 43 (1), 61 – 68. Abstract
Acerini, C.L., Harris, D.A., Matyka, K.A., Watts, A.P., Umpleby, A.M., Russell-Jones, D.L., Dunger, D.B. Effects of low doses of recombinant human insulin-like growth factor I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin dependent diabetes mellitus. Metabolism 1998; 47: 1481 – 1489.Abstract
Acerini C.L., Patton C.M., Savage M.O., Kernell A., Westphal O, Dunger, D.B. Randomised placebo-controlled trial of human recombinant insulin-like growth factor-I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997; 350: 1199 – 1204. Abstract